Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome

Pediatric Blood and Cancer

Volumn 52, Issue 1, 2009, Pages 14-19

  Shah, Niketa ^a   Al Ahmari, Ali ^a   Al Yamani, Arwa ^a   Dupuis, Lee ^a,b   Stephens, Derek ^a   Hitzler, Johann ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

ALL; Chemotherapy; Down syndrome; Methotrexate; Toxicity; Trisomy 21

Indexed keywords

FOLINIC ACID; METHOTREXATE; OPIATE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANDIDA MENINGITIS; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN SYNDROME; DRUG CLEARANCE; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC TOXICITY; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INTENSIVE CARE; JUGULAR VEIN THROMBOSIS; LUNG DISEASE; MAINTENANCE THERAPY; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL TOXICITY; NEPHROTOXICITY; ORBITAL CELLULITE; OVERALL SURVIVAL; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RESPIRATORY TOXICITY; RETROSPECTIVE STUDY; SKIN TOXICITY; STEM CELL TRANSPLANTATION; THERAPY DELAY; THROMBOCYTE TRANSFUSION; VEIN OCCLUSION; VULVOVAGINITIS; DOSE RESPONSE; MORTALITY; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; HUMANS; MATCHED-PAIR ANALYSIS; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 58149385367     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21737     Document Type: Article

References (33)

1. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia; Report of a nationwide survey. Am J Dis Child 1957;94:289-293.
2. Avet-Loiseau H, Mechinaud F, Harousseau JL. Clonal hematologic disorders in Down syndrome. A. review. J Pediatr Hematol Oncol 1995;17:19-24.
3. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: A review. Pediatr Hematol Oncol 1992;9:139-149.
4. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000;355:165-169.
5. Bassal M, La MK, Whitlock JA, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer 2005;44:21-28.
6. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: Clinical features and response to treatment. Arch Dis Child 2001;85:321-325.
7. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 2002;359:1019-1025.
8. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998;12:645-651.
9. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A. pediatric oncology group study. Cancer 1991;67:1057-1063.
10. Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987;111:606-612.
11. Nathan PC, Maze R, Spiegler B, et al. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation. Pediatr Blood Cancer 2004;42:24-29.
12. Winick N, Martin PL, Devidas M, et al. Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: A children's oncology group study (COG). ASH Annu Meet Abstr 2007;110:583.
13. Gaynon PS, Camitta BC, Matloub Y, et al. Outcomes for B-precursor patients in legacy children's cancer group (CCG) and pediatric oncology group (POG) studies in childhood acute lymphoblastic leukemia (ALL): A children's oncology group (COG) report. ASH Annu Meet Abstr 2007;110:847.
14. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A. relapse study of the BFM group. Blood 1991;78:1166-1172.
15. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003;101:3835-3839.
16. Hosmer JJ, Lemeshow S. Applied survival analysis: Regression modeling of time to event data. New York:John Wiley; 1999.
17. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-1289.
18. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2005;106:4043-4049.
19. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 1993;11:1361-1367.
20. Frost BM, Gustafsson G, Larsson R, et al. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: An explanation to differences in clinical outcome? Leukemia 2000;14:943-944.
21. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-251.
22. Robison LL, Nesbit ME Jr, Sather HN, et al. Down syndrome and acute leukemia in children: A 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr 1984;105:235-242.
23. Lanza C, Volpe G, Basso G, et al. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome. Leukemia 1997;11:820-821.
24. Arico M, Ziino O, Valsecchi MG, et al. Acute lymphoblastic leukemia and Down syndrome: Presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer 2008.
25. Steiner M, Attarbaschi A, Konig M, et al. Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome. Pediatr Hematol Oncol 2005;22:229-234.
26. Ugazio AG, Maccario R, Notarangelo LD, et al. Immunology of Down syndrome: A review. Am J Med Genet Suppl 1990;7:204-212.
27. Roizen NJ, Amarose AP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet 1993;46:510-512.
28. Novo E, Garcia MI, Lavergne J. Nonspecific immunity in Down syndrome: A study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet 1993;46:384-391.
29. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990;65:212-216.
30. Atra A, Richards SM, Chessells JM. Remission death in acute lymphoblastic leukaemia: A changing pattern. Arch Dis Child 1993;69:550-554.
31. Blatt J, Albo V, Prin W, et al. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet 1986;2:914.
32. Peeters MA, Poon A, Zipursky A, et al. Toxicity of leukaemia therapy in children with Down syndrome. Lancet 1986;2:1279.
33. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 2005;44:33-339.